Touchlight

Where does plasmid DNA still win, and where does Cell-Free DNA outperform? Watch as experts break down real-world data and what it means for next-gen gene therapy. Get the insights today in this on-demand webcast.

Where does plasmid DNA still win, and where does Cell-Free DNA outperform? Watch as experts break down real-world data at scale and what it means for next-gen gene therapy. Get the insights today in this on-demand webcast.

Is Plasmid Still the Right DNA for Your Program? See how plasmid and cell-free DNA compare across scalability, complexity, timelines, and the evolving needs of advanced gene therapies. WATCH THE DEBATE

Is plasmid DNA creating an unnecessary bottleneck in your LVV process? See comparative data across multiple LVV system generations and explore how cell-free doggybone DNA

Watch this On-Demand Webcast and hear how Touchlight and ElevateBio are enabling safer and more effective cell and gene therapies.

DNA input choice plays a vital role in AAV manufacturing economics, influencing both process efficiency and overall cost of goods. Explore economic modelling that examines the cost impact of plasmid DNA and the potential efficiencies of alternative DNA inputs as programs move toward commercial scale. Download the article to see the analysis.